ES2039252T3 - Metodo para preparar un medicamento destinado a tratar la sobrecarga de hierro. - Google Patents

Metodo para preparar un medicamento destinado a tratar la sobrecarga de hierro.

Info

Publication number
ES2039252T3
ES2039252T3 ES198787310300T ES87310300T ES2039252T3 ES 2039252 T3 ES2039252 T3 ES 2039252T3 ES 198787310300 T ES198787310300 T ES 198787310300T ES 87310300 T ES87310300 T ES 87310300T ES 2039252 T3 ES2039252 T3 ES 2039252T3
Authority
ES
Spain
Prior art keywords
preparing
iron overload
treat iron
medicine intended
iron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787310300T
Other languages
English (en)
Inventor
John William Adamson
Michael Richard Downing
Joseph Wetherill Eschbach
Joan Christine Egrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen K A Inc
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Application granted granted Critical
Publication of ES2039252T3 publication Critical patent/ES2039252T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Water By Oxidation Or Reduction (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Manufacture Of Iron (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Compounds Of Iron (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogen, Water And Hydrids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBE UN METODO PARA DISMINUIR LA RESERVA DE HIERRO Y EL HIERRO EN EL SUERO EN MAMIFEROS. EN PARTICULAR, A UN MAMIFERO QUE TIENE UN DESORDEN POR SOBRECARGA DE HIERRO, SE ADMINISTRA UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE ERITROPROYETINA PARA AUMENTAR LA PRODUCCION DE CELULAS ROJAS DE SANGRE, Y SUBSIGUIENTEMENTE SE FLEBOTOMIZA EL MAMIFERO PARA ELIMINAR EL EXCESO DE CELULAS ROJAS DE SANGRE PRODUCIDAS.
ES198787310300T 1986-11-21 1987-11-20 Metodo para preparar un medicamento destinado a tratar la sobrecarga de hierro. Expired - Lifetime ES2039252T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/933,495 US5013718A (en) 1986-11-21 1986-11-21 Method for treating iron overload using EPO

Publications (1)

Publication Number Publication Date
ES2039252T3 true ES2039252T3 (es) 1993-09-16

Family

ID=25464076

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787310300T Expired - Lifetime ES2039252T3 (es) 1986-11-21 1987-11-20 Metodo para preparar un medicamento destinado a tratar la sobrecarga de hierro.

Country Status (16)

Country Link
US (1) US5013718A (es)
EP (1) EP0269394B1 (es)
JP (1) JPH0692316B2 (es)
KR (1) KR950009100B1 (es)
AT (1) ATE68352T1 (es)
AU (1) AU602028B2 (es)
CA (1) CA1322165C (es)
DE (1) DE3773852D1 (es)
DK (1) DK167650B1 (es)
ES (1) ES2039252T3 (es)
GR (1) GR3003254T3 (es)
IE (1) IE60865B1 (es)
IL (1) IL84275A (es)
NZ (1) NZ222432A (es)
PT (1) PT86187B (es)
WO (1) WO1988003808A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO881507D0 (no) * 1987-04-10 1988-04-07 Ortho Pharma Corp Fremgangsmaate for forhoeyning av hematokritnivaaet til et normalt pattedyr.
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1996014081A1 (en) * 1994-11-03 1996-05-17 Boehringer Mannheim Gmbh Use of erythropoietin in the treatment of rheumatoid arthritis
CA2216443A1 (en) 1995-03-31 1996-10-03 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
EP0965349A1 (de) * 1998-06-18 1999-12-22 Roche Diagnostics GmbH Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
AU3269101A (en) * 1999-11-12 2001-06-06 James C. Barton Diagnostic test for hemochromatosis
US7160855B2 (en) * 2002-03-14 2007-01-09 Children's Hospital & Research Center At Oakland Enhancement of iron chelation therapy
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
KR101248252B1 (ko) 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
WO2012174157A1 (en) * 2011-06-13 2012-12-20 Cedars-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
US10694962B2 (en) 2011-06-13 2020-06-30 Cedars-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
FR3037592B1 (fr) 2015-06-18 2017-06-09 Michelin & Cie Pneumatique pourvu d'une bande de roulement comprenant un elastomere dienique et un systeme d'elastomeres thermoplastiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification

Also Published As

Publication number Publication date
IL84275A (en) 1993-04-04
IE873113L (en) 1988-05-21
AU8179487A (en) 1988-06-16
KR890700032A (ko) 1989-03-02
DE3773852D1 (de) 1991-11-21
EP0269394A3 (en) 1988-09-14
EP0269394A2 (en) 1988-06-01
WO1988003808A1 (en) 1988-06-02
US5013718A (en) 1991-05-07
DK167650B1 (da) 1993-12-06
PT86187A (en) 1987-12-01
PT86187B (pt) 1990-11-07
IE60865B1 (en) 1994-08-24
CA1322165C (en) 1993-09-14
ATE68352T1 (de) 1991-11-15
DK407488D0 (da) 1988-07-21
DK407488A (da) 1988-07-21
AU602028B2 (en) 1990-09-27
JPS63159322A (ja) 1988-07-02
GR3003254T3 (en) 1993-02-17
JPH0692316B2 (ja) 1994-11-16
KR950009100B1 (ko) 1995-08-14
NZ222432A (en) 1990-07-26
EP0269394B1 (en) 1991-10-16

Similar Documents

Publication Publication Date Title
ES2039252T3 (es) Metodo para preparar un medicamento destinado a tratar la sobrecarga de hierro.
ES2007341A6 (es) Un procedimiento para producir m-csf
KR880701736A (ko) Il-6의 제조방법 및 용도
PT87086A (pt) Active specific immune suppression
RU93052390A (ru) Способ лечения шизофрении, применение комбинации арахидоновой и докозагексановой кислот для получения лекарственного средства для лечения шизофрении
IT1203462B (it) Cella per la centrifugazione in continuo del sangue
EP0177137A3 (en) White blood cell differentiation composition and method
FR2591892B1 (fr) Association collagene/principe actifantiseptique et/ou anti-inflammatoire a titre de composition, son procede de preparation et son utilisation pour la fabrication d'une composition pharmaceutique
PT87197A (pt) Processo para preparacao de agentes terapeuticos eritropoietina
FR2608050B1 (fr) Procede de preparation d'un melange peptidique riche en di- et tri-peptides, utilisable notamment en nutrition artificielle et en dietetique, melange ainsi obtenu, et utilisation de ce melange en nutrition artificielle et en dietetique
ES536055A0 (es) Un procedimiento para la produccion de un complejo covalentemente enlazado de heparina-antitrombina-iii
OA07002A (fr) Dérivé de la pyrrolidine, sa préparation et ses utilisations thérapeutiques pour le traitement de l'insuffisance cérébrale.
OA09455A (fr) Nouveaux polyols furanniques, utilisation de ceux-ci comme polyols dans la formation de polyuréthannes, polyuréthannes ainsi obtenus et leur procédé de préparation.
ES8706110A1 (es) Un procedimiento para la preparacion de derivados de alfa-aminoalquil-alfa-alquilfenilacetonitrilo.
EP0248217A3 (en) Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
HUT45897A (en) Process for production of medicines with big acid-fixing capacity, prolonged in time effect, increased bioutilty, neutralizing gastric acid
ES428172A1 (es) Un procedimiento para preparar acido 5-pivaloiloxi-5-(1-fe-niletil)-barbiturico.
BR8004546A (pt) Composto terapeutico, processo e composicao terapeuticos apropriados para aliviar inflamacao e dores, e para producao de plaquetas de sangue em um corpo de animal vivo
SU672041A1 (ru) Ременна центрифуга дл формовани тел вращени
ES537158A0 (es) Procedimiento para mejorar la extraccion del acido clavulanico
ES457992A1 (es) Un procedimiento para preparar nuevas sales por adicion de acido del d-(+)-1-(3-hidroxifenil)-2-aminopropano.
ES535613A0 (es) Procedimiento para la preparacion de una pomada de acidos pirogalico y salicilico, util en el tratamiento de la psoriasis
NZ194053A (en) Method of obtaining reproduction in female animals with symptom-free sterility
PT82277A (en) Method for enhancement of absorption of proteins with medicinal properties
AU7931487A (en) Therapeutic treatment of abnormal cell growth with follicle regulatory protein

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 269394

Country of ref document: ES